Conferences
22–24 March 2024, Sapporo, Japan/Online
The 1st International Symposium on Cancer Immunology and Immunotherapy
We cordially invite you to attend the symposium organized by the Japanese Association of Cancer Immunology (JACI).
It will take place on 22–24 March 2024, in Sapporo, Japan, on-site and online in collaboration with SITC and MDPI.
Conference Chair
Toshihiko Torigoe, MD, PhD
Professor and Chairman, Department of Pathology 1, Sapporo Medical University
President of the Japanese Association of Cancer Immunology (JACI)
Editor-In-Chief of MDPI’s Immuno, an international, peer-reviewed, open access journal on immunological research
Topics of Interest:
A. New Technology for Immuno-Oncology Research;
B. Senescence and Cancer Immunity;
C. Spatial Biology and the Tumor Microenvironment;
D. New Modality with T-cell and Antibody Engineering;
E. Clinical Immuno-Oncology and Translational Research.
Invited Speakers:
Dr. Leisha A. Emens (SITC President, ANKYRA Therapeutics, USA): Video lecture;
Dr. Erwei Song (Sun Yat-Sen University, Guangzhou, China): On-site;
Dr. Thales Papagiannakopoulos (New York University, USA): On-site;
Dr. Wouter Scheper (Netherlands Cancer Institute, The Netherlands): On-site;
Dr. Matthew M. Gubin (MD Anderson Cancer Center, USA): Online lecture;
Dr. Hiroyoshi Nishikawa (National Cancer Center Japan, Nagoya University, Japan);
Dr. Yutaka Kawakami (International University of Health and Welfare, Japan);
And another 11 speakers from JACI.
https://jaci2024.com/invitedspeakers.html
Important Dates
Abstract submission deadline: 3 March 2024
Registration deadline: 20 March 2024
Guide for Authors
To submit your abstract, please visit the following link: https://jaci2024.com/abstracts.html
To register for the event, please visit the following link: https://jaci2024.com/registration.html
For any enquiries regarding the event, please contact us through the following email address: jaci2024@sapmed.ac.jp
We look forward to seeing you at the 1st International Symposium on Cancer Immunology and Immunotherapy in Sapporo, Japan.